PRME
Price
$5.36
Change
-$0.21 (-3.77%)
Updated
May 8, 6:59 PM EST
One day until earnings call
RLAY
Price
$6.51
Change
-$0.23 (-3.41%)
Updated
May 8, 6:59 PM EST
91 days until earnings call
Ad is loading...

PRME vs RLAY

Header iconPRME vs RLAY Comparison
Open Charts PRME vs RLAYBanner chart's image
Prime Medicine
Price$5.36
Change-$0.21 (-3.77%)
Volume$428.79K
CapitalizationN/A
Relay Therapeutics
Price$6.51
Change-$0.23 (-3.41%)
Volume$631.22K
CapitalizationN/A
View a ticker or compare two or three
PRME vs RLAY Comparison Chart

Loading...

PRMEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RLAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
PRME vs. RLAY commentary
May 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and RLAY is a Hold.

COMPARISON
Comparison
May 08, 2024
Stock price -- (PRME: $5.57 vs. RLAY: $6.74)
Brand notoriety: PRME and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 93% vs. RLAY: 108%
Market capitalization -- PRME: $668.56M vs. RLAY: $892.69M
PRME [@Biotechnology] is valued at $668.56M. RLAY’s [@Biotechnology] market capitalization is $892.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $567.57B to $0. The average market capitalization across the [@Biotechnology] industry is $2.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 5 TA indicator(s) are bullish while RLAY’s TA Score has 5 bullish TA indicator(s).

  • PRME’s TA Score: 5 bullish, 3 bearish.
  • RLAY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both PRME and RLAY are a good buy in the short-term.

Price Growth

PRME (@Biotechnology) experienced а +13.21% price change this week, while RLAY (@Biotechnology) price change was +3.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.03%. For the same industry, the average monthly price growth was -4.77%, and the average quarterly price growth was +71.17%.

Reported Earning Dates

PRME is expected to report earnings on May 09, 2024.

RLAY is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Biotechnology (+1.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for PRME with price predictions.
OPEN
A.I.dvisor published
a Summary for RLAY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RLAY($893M) has a higher market cap than PRME($669M). PRME (-37.133) and RLAY (-38.783) have similar YTD gains .
PRMERLAYPRME / RLAY
Capitalization669M893M75%
EBITDAN/AN/A-
Gain YTD-37.133-38.78396%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
PRMERLAY
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
66%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 16 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 6 days ago
65%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
PRMEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RLAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLIFX15.640.13
+0.84%
Lazard Global Listed Infrastructure Inst
AFYCX24.050.11
+0.46%
Bahl & Gaynor Income Growth C
IGNYX17.320.01
+0.06%
Delaware Ivy Natural Resources Y
TEQCX24.92-0.01
-0.04%
Touchstone Non-US ESG Equity C
MLMSX19.06-0.16
-0.83%
Morgan Stanley Instl Global Core R6

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+3.15%
BEAM - PRME
63%
Loosely correlated
-1.10%
NTLA - PRME
62%
Loosely correlated
+0.67%
RLAY - PRME
55%
Loosely correlated
-4.53%
XNCR - PRME
53%
Loosely correlated
-0.29%
ABCL - PRME
50%
Loosely correlated
-1.70%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with PRME. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
-4.53%
PRME - RLAY
55%
Loosely correlated
+3.15%
NTLA - RLAY
53%
Loosely correlated
+0.67%
XNCR - RLAY
49%
Loosely correlated
-0.29%
ADPT - RLAY
49%
Loosely correlated
-3.42%
BEAM - RLAY
49%
Loosely correlated
-1.10%
More